WEDNESDAY, Feb. 9 (HealthDay News) -- Genetic sequencing of the
entire prostate cancer cell genome revealed never-before-seen
changes in DNA that may contribute to tumor growth, new research
By mapping the full genetic blueprint of the tumor, researchers
hope the information will eventually lead to the development of
more targeted drugs and a better understanding of which prostate
cancers are likely to spread, one of the biggest challenges for
physicians and patients.
"With additional studies and as we sequence more prostate cancer genomes, we may be able to distinguish benign from more aggressive prostate cancers and prevent unnecessary surgeries and treatments," said lead study author Michael Berger, now an assistant professor of pathology at Memorial Sloan-Kettering Cancer Center in New York City.
In the study, researchers mapped the complete genome of prostate
cancer -- that is, all genetic material, including more than 20,000
genes and other DNA material surrounding the genes, for seven
patients with advanced disease. The researchers then compared the
cancer genome in the tumors to the normal genome in white blood
cells taken from the same patients.
The investigators found various types of genetic alterations,
some of which had previously been identified and others that had
never been seen before. Of particular note were structural
rearrangements in which relatively large chunks of DNA from one
chromosome move to another location, or swap places with other
pieces of DNA. These rearrangements can create "fusion genes,"
prevent genes from working or let the gene operate unchecked,
leading to out-of-control cell growth and cancer, the authors
The sequencing revealed nearly 100 such rearrangements in each
patient, said Berger.
DNA rearrangements tend to happen more as cancer progresses and
the cells become more fragile and damaged, but some of the
rearrangements may turn out to be important to the development of
the cancer in the first place, he added.
"We are doing whole genome sequencing as opposed to more targeted sequencing because it's really necessary to identify these rearrangements which are so important in prostate cancer," Berger said.
The study, conducted by researchers from the Broad Institute,
Dana-Farber Cancer Institute and Weill Cornell Medical College,
appears in the Feb. 10 issue of
Until recently, such DNA rearrangements were known to be
important in blood cancers such as lymphoma and leukemia, said
William Phelps, program director for Translational and Preclinical
Cancer Research at the American Cancer Society. However, it's only
more recently that researchers have started uncovering the
importance of that type of genetic alteration in solid tumors such
as breast and now, prostate cancers, he said.
Here's one way to conceptualize the alteration, Phelps said: "If
the genome was a book, instead of just looking for out-of-place
letters or misspelled words, whole genome sequencing looks for
whole paragraphs that are in the wrong place.
"Because [the researchers] sequenced everything, they were able to map not only individual base changes but also how whole genes or segments of the chromosomes had moved around," Phelps said. "By sequencing everything and comparing the normal DNA (in white blood cells), they could see that not only were there individual base changes in the genes, but the genes themselves had been reshuffled in the tumor as part of the process of becoming cancer," he explained.
"If we could use those changes as a diagnostic tool that would be tremendously valuable," he added.
Whole genome sequencing also enables scientists to look not only
at "coding" genes, but also "noncoding" DNA around the genes that
was once thought to be "junk" but is now known to play an important
regulatory role within cells, Phelps said.
Prostate cancer causes more than 30,000 deaths in the United
States annually, according to background information in the
article. More than 200,000 men are diagnosed each year.
Currently, it's difficult for physicians to know if prostate
cancer is going to be slow-growing, in which case doctors may
monitor but not treat it, or if it will be aggressive, in which
case surgery and chemotherapy may be needed, said Dr. Anna Ferrari,
director of the Genitourinary Cancer Program at the NYU Cancer
The researchers "have done a complete sequencing of the genome
in prostate cancers that are very aggressive, and they found in
addition to the already established alterations, new genes and new
pathways that may influence the progression of the disease,"
Ferrari said. "This may point to new targets for drug development
and treatment strategies."
U.S. National Cancer Institute has more on
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.